Notice of Interim Results & Investor Presentation
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 12 March 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, will announce its unaudited interim results for the six months ended 31 December 2024 on Tuesday 18 March 2025.
Investor Presentations
On-line investor presentation
Julian Baines, Executive Chairman, will be hosting a live interactive presentation on the Engage Investor platform, at 2:00pm (GMT) on 18 March 2025.
Renalytix welcomes all current shareholders and interested investors to join and encourages investors to pre-submit questions. Investors can also submit questions at any time during the live presentation.
Investors can sign up to Engage Investor at no cost and follow Renalytix plc from their personalised investor hub. Register interest in this event here: https://engageinvestor.news/RENX_IP25
A recording of the event will be available on the Engage Investor platform afterwards.
In-person investor presentation
Julian Baines will also provide an in-person presentation relating to the Company's interim results at 5.30pm GMT on Tuesday 25 March 2025, which is open to all existing and potential shareholders. The Company welcomes investors to 75 King William Street, London, EC4N 7BE from 5.15pm for a 5.30pm start and will be followed by refreshments.
If you would like to attend, please contact Walbrook PR on 020 7933 8780 or email renalytix@walbrookpr.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.